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Summary
How cytotoxic T lymphocytes (CTLs) kill intracellular
pathogens without killing themselves has been a re-
curring question ever since their discovery. By using
mice deficient in Serine Protease Inhibitor 6 (Spi6),
we show that by inhibiting granzymeB (GrB), Spi6 pro-
tects CTLs from self-inflicted injury. Infection with ei-
ther Lymphocytic Choriomeningitis virus (LCMV) or
Listeria monocytogenes (LM) revealed increased apo-
ptosis and diminished survival of Spi6 knockout (KO)
CTLs, which was cell autonomous and could be cor-
rected by GrB deficiency. Spi6 KO mice in turn were
impaired in their ability to clear LCMV infection. Spi6
KOCTLs revealed a breakdown in the integrity of cyto-
toxic granules, increased cytoplasmic GrB, and ensu-
ing apoptosis. We conclude that Spi6 protects CTLs
from suicide caused by GrB-mediated breakdown of
cytotoxic granules.
Introduction
Contact-dependent, lymphocyte-mediated cytotoxicity
proceeds through two pathways. The first pathway is
triggered by members of the Tumor Necrosis Factor Re-
ceptor family, of which Fas is the most important (Kagi
et al., 1996). The second involves the exocytosis of pro-
teins present in CD8+ cytotoxic T lymphocyte (CTL) and
natural killer (NK) cell granules (Millard et al., 1984; Po-
dack et al., 1985). The exocytosis pathway affords the
rapid and targeted destruction of infected or damaged
cells. Exocytosis of perforin (Pfn) (Kagi et al., 1994a;
Podack et al., 1985) facilitates the entry of serine prote-
ases called granzymes, which trigger apoptosis in target
cells (Shi et al., 1992). Granzymes A and B are the most
abundant granzymes in mice and humans and are the
best characterized (Russell and Ley, 2002). Granzyme B
(GrB) activates the caspase-dependent pathways of ap-
optosis and, like caspases, cleaves after aspartic acid
residues, whereas granzyme A (GrA), which is a tryptase,
cleaves after basic amino acids. Recent studies indicate
that the mechanisms by which different granzymes op-
erate are discrete, providing failsafe mechanisms to de-
stroy tumors or pathogens that have devised ways to
evade a given pathway (Lieberman, 2003).
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pathway of death, it is not surprising that CTLs and NK
cells are susceptible to self-inflicted damage. The role
of the exocytosis pathway in CTL apoptosis has been
clearly shown by Pfn-deficient CTLs, which are defective
in granule-mediated killing (Kagi et al., 1994a, 1994b) but
also undergo less apoptosis in vitro (Spaner et al., 1998).
When challenged in vivo with allografts (Spaner et al.,
1999), viruses, or intracellular bacteria (Badovinac
et al., 2000, 2003; Kagi et al., 1999; Matloubian et al.,
1999), Pfn-deficient CTLs undergo a massively in-
creased expansion compared to wild-type controls.
It is unclear how granzymes are turned against CTLs.
The traffic of granzymes into a target cell is achieved
by the unidirectional exocytosis of cytotoxic granules
into the secretory synapse (Kupfer et al., 1986). There-
fore, the simplest explanation for CTL self-destruction
is that CTLs become the targets for killing by other CTLs
(Hanon et al., 2000; Huang et al., 1999; Walden and
Eisen, 1990) (fratricide). Although the delivery of gran-
zymes to target cells is highly ordered (Trambas and
Griffiths, 2003), endogenous granzymes may become
‘‘misdirected’’ into the cytoplasm and so a cytotoxic
lymphocyte may die through suicide (Ida et al., 2003).
Despite the propensity for self-inflicted damage, CTLs
can kill several targets in succession without killing
themselves (Zagury et al., 1975). Therefore, it has been
suggested that cytotoxic lymphocytes can protect
themselves from self-inflicted damage (Trambas and
Griffiths, 2003).
Homeostatic regulation of serine proteases is mainly
achieved through interaction with inhibitors belonging
to the Serine Protease Inhibitor (serpin) superfamily (Sil-
verman et al., 2001). Inhibitory serpins have a common
mode of action: each contains a variable C-terminal re-
active center loop (RCL) resembling the substrate of its
cognate protease. On protease binding, the RCL is
cleaved between the two residues designated P1 and
P’1 and it undergoes a conformational change that dis-
torts the protease and irreversibly locks the serpin-
protease complex. The human serpin, Proteinase Inhib-
itor 9 (PI9), is a potent inhibitor of GrB (Sun et al., 1996). In
mice, Serine Protease Inhibitor 6 (Spi6), a homolog of
PI9, can also inhibit GrB in vitro (Sun et al., 1997) and is
expressed in CTLs and NK cells (Phillips et al., 2004).
Both PI9 and Spi6 lack signal secretory sequences and
so are located in the cytoplasm (Sun et al., 1996, 1997).
Spi6 is upregulated upon the maturation of dendritic
cells (DCs) (Medema et al., 2001a), and overexpression
protects targets from CTL killing (Medema et al.,
2001b). Transgenic Spi6 can increase the number of
CD8 T cells that persist long after virus clearance (Phil-
lips et al., 2004). However, GrB KO mice do not show
any increase in the number of CTLs after infection with
virus and so it is not clear if GrB induces CTL apoptosis
(Phillips et al., 2004). Therefore, whether inhibition of
GrB is a physiologically relevant mechanism by which
Spi6 protects CTLs remains to be determined. To test
this hypothesis, we generated Spi6-deficient mice
(Spi6 knockout [KO] mice). The survival of Spi6 KO
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452Figure 1. Spi6-Deficient Mice
(A) Homologous recombination between the Spi6 targeting vector and wild-type allele in ES cells as detected by altered restriction fragments
[Hind III (H), Spe I (S)] using 50 and 30 external probes. Cre-induced loxP (filled arrows) mediated excision of neo, resulting in restriction fragments
of altered size (kb).
(B) Southern blots of two ES cell clones with wild-type (WT: 37) or mutant (M: 69 and 389) Spi6 neo alleles.
(C) A clone derived from 389 harboring an allele in which neo has been excised (Spi6Dneo).
(D) Spi6+/2 mice were intercrossed and progeny genotyped by Southern blot.
(E) Spi6 mRNA expression determined by real-time PCR and expressed as a ratio compared with the control cyclofilin A. Cells were purified from
four mice and pooled and mRNA was prepared. Histograms are the mean of three determinations.
(F) Spi3 and Spi6mRNA levels determined from splenocytes by real-time PCR as in (E). Histograms are the mean of two determinations from four
mice (6SEM). There was no significant difference between the levels of Spi3 mRNA in splenocytes from B6 compared to Spi6 KO mice (p = 0.85).CTLs specific for LCMV or LM was drastically impaired
due to increased GrB-mediated apoptosis. Spi6 pro-
tected CTLs from apoptosis by inactivating GrB in the
cytoplasm through the formation of SDS-stable com-
plexes indicative of a serpin:protease interaction. To
our surprise, Spi6 was required to ensure the integrity of
exocytic cytotoxic granules through the inhibition of GrB-
mediated breakdown. These findings demonstrate the
requirement for an endogenous inhibitor of GrB to pro-
tect CTLs from suicide caused by granule breakdown.
Results
Impaired Survival of Spi6-Deficient CTLs
To address the role of the GrB inhibitor Spi6 (Serpin b9)
(Sun et al., 1997) in the protection of CTLs from self-
inflicted damage, we generated Spi6-deficient mice.
By means of homologous recombination in ES cells
from C57BL/6 mice (B6 mice), we deleted exon 7, which
encodes 60% of Spi6 and includes the critical reactive
center loop (RCL), which is required for target proteaseinhibition (Sun et al., 1997) (Figures 1A and 1B). By Cre-
mediated recombination, the G418-resistance cassette
was removed (Figure 1C) to avoid affecting the tran-
scription of closely linked serpin genes such as Spi3
(Serpin b6a) (Sun et al., 1997; Kaiserman et al., 2002).
Mice homozygous for Spi6 mutant alleles in the B6
background (Spi6 KO mice) were generated (Figure 1D).
Real-time PCR for the Spi6 RCL region revealed the ex-
pression of Spi6 mRNA in both myeloid and lymphoid
cells from B6 but not Spi6 KO mice (Figure 1E). The mu-
tation of the Spi6 locus did not affect the expression of
Spi3 mRNA in Spi6 KO splenocytes (Figure 1F). The de-
velopment of leukocytes was not affected by the Spi6
mutation because Spi6 KO mice did not display any sig-
nificant difference in the number of myeloid or lymphoid
cells in the thymus or blood (see Tables S1 and S2 in the
Supplemental Data available with this article online).
Spi6 is upregulated in CTLs, and overexpression can
inhibit GrB-mediated apoptosis in vitro (Phillips et al.,
2004). To examine the physiological role of Spi6, we ex-
amined the CTL response of Spi6 KO mice to infection.
Spi6 Protects CTLs from Granzyme B
453Figure 2. Impaired Survival and Function of Spi6 KO CTLs
B6 or Spi6 KO mice were infected with either LCMV Armstrong (2 3 105 pfu/mouse i.p.) or LM DPL-1942-OVA (105 cfu/mouse i.v.).
(A) Percentage (upper right corner) of gp33+ CD8+ and YOPRO-1+ cells.
(B) Mean number gp33+ CD8+ cells 6 SEM (n = 5 mice).
(C) Mean percentage YOPRO-1+ of gp33+ CD8+ 6 SEM (n = 5 mice).
(D) Percentage OVA+ CD8+ and YOPRO-1+ cells.
(E) Mean number of OVA+ CD8+ spleen cells 6 SEM (n = 5 mice).
(F) Mean percentage of YOPRO-1+ of OVA+ CD8+ 6 SEM (n = 5 mice).Mice were infected with LCMV Armstrong (Phillips et al.,
2004) and the attenuated DPL-1942 strain of LM, which
had been engineered to express ovalbumin and gener-
ate an H-2Kb-restricted peptide antigen (OVA) (Pope
et al., 2001). To avoid the effects of persistent antigen
on interferon-driven apoptosis (Badovinac et al., 2000),
we used doses of LCMV Armstrong (2 3 105 pfu) and
LM DPL-1942 (105 cfu) that result in complete clearance
in both B6 and Spi6 KO mice after 8 days. Staining with
gp 33/H-2Db-tetramers revealed that the number of CTL
specific for LCMV Armstrong was diminished in Spi6 KO
mice compared to B6 controls (5-fold lower, p = 3 3
1029) (Figures 2A and 2B). Furthermore, Spi6 KO mice
harbored about nine times (p = 2 3 10211) less LM-spe-
cific CTLs after infection (Figures 2D and 2E). In contrast
to the deficit in CTLs, there was no significant difference
in the number of CD4 T lymphocytes, B lymphocytes, NK
cells, or macrophages either 8 or 14 days after LCMV
infection (Table S3).
The lower number of CTLs in Spi6 KO mice correlated
with an increase in the onset of apoptosis of both LCMV
(Figures 2A and 2C) and LM-specific CD8 T cells (Figures
2D and 2F), as evidenced by increased staining with the
DNA dye YOPRO-1, which is a robust measure of apopto-
sis based on alterations in chromosomal DNA structure
(Idziorek et al., 1995; Liu et al., 2004; Opferman et al.,
2001; Phillips et al., 2004). Thus, Spi6 is required for the
survival and protection of CTLs from apoptosis in vivo.
Defective Survival of Spi6 KOCTLs IsGrBDependent
and Cell Autonomous
We determined whether inhibition of GrB was a physio-
logical mechanism by which Spi6 ensured the survivalof CTLs. To do this, we examined the effect of GrB defi-
ciency in Spi6 KO x GrB cluster-deficient (GrB KO) mice
(Heusel et al., 1994). After infection, the number of LCMV-
specific CTLs in GrB KO mice is the same as in wild-type
mice (Phillips et al., 2004; Zajac et al., 2003), possibly be-
cause other homeostatic factors also act to maintain
a normal clonal burst size (Jameson, 2002). As we ob-
served before, there was a 4-fold decrease in the recov-
ery (Figure 3A) and a significant (p = 73 1028) increase in
apoptosis (Figure 3B) of LCMV-specific CTLs in Spi6 KO
mice. In Spi6 KO x GrB KO mice, the number (Figure 3A)
andproportionofCTLsundergoing apoptosis (Figure3B)
were the same as B6 controls. Thus, the absence of GrB
corrected the deficit in CTL survival caused by Spi6 de-
ficiency and returned the level of LCMV-specific CTLs
to wild-type levels. GrB KO mice have partially reduced
expression of the linked granzymes C and F (Revell
et al., 2005), which may also contribute to the correction
of CTL survival in Spi6 KO mice. However, Spi6 directly
inhibits purified GrB in vitro (Sun et al., 1997) (data not
shown) and protects perforin-loaded cells from purified
GrB (Phillips et al., 2004). Therefore, we conclude that
protection from GrB is at least in part a physiological
mechanism by which Spi6 ensures the survival of CTLs
after infection.
Spi6 can protect DCs from granule-mediated killing by
CTLs (Medema et al., 2001a), and so reduced expansion
of CTLs caused by defective priming may occur in Spi6
KO mice. We determined whether the requirement for
Spi6 for CTL survival was cell autonomous. Spi6 KO
mice were crossed with C57BL/6 P14 transgenic mice,
which express a T cell receptor (TCR) specific for the
gp33 peptide antigen of LCMV in the context of H-2Db
Immunity
454Figure 3. Effect of Spi6 on CTLs Is Depen-
dent on GrB
B6 and Spi6 KO mice were infected with
LCMV Armstrong (2 3 105 pfu/mouse i.p.),
and then after 8 days the (A) mean number
of gp33+ CD8+ spleen cells and (B) mean per-
centage YOPRO-1+ of gp33+ CD8+ cells were
determined. P14 CD8 T cells (104) were puri-
fied from B6 or Spi6 KO mice (CD45.2+) and
adoptively transferred to B6 CD45.1+ con-
genic mice, and then the (C) mean number
of donor LCMV-specific (CD45.2+ gp33+
CD8+) and (D) mean percentage of YOPRO-1+
donor cells determined. Recipient mice were
infected and fed BrdU for 8 days, and then
the (E) mean percentage BrdU+ donor cells de-
termined. All means are6 SEM (n = 5 mice).(Pircher et al., 1990). Naive P14 CD8 T cells (>90% pure)
from Spi6 KO and B6 mice (CD45.2+) were adoptively
transferred into B6 CD45.1 congenic recipients, which
were then infected with LCMV. After 8 days, the number
of donor LCMV-specific CTLs (CD45.2+) from Spi6 KO
mice was diminished by 7-fold (p = 33 1028) compared
to B6 P14 donor cells (Figure 3C). Therefore, the require-
ment for Spi6 in CTLs is cell intrinsic. As for the whole
animal experiments, there was a significant (p = 0.04)
increase in the proportion of donor Spi6 KO CTLs under-
going apoptosis after adoptive transfer to wild-type
recipients (Figure 3D). There was, however, no signifi-
cant difference (p = 0.2) in the rate of cell division of do-
nor Spi6 CD8 T cells compared to B6 controls over the 8
day expansion period after LCMV infection (Figure 3E).
Thus, the diminished recovery of donor Spi6 KO CTLs
is a result of impaired survival due to increased apopto-
sis rather than impaired expansion.
Impaired CTL Immunity to Virus
in Spi6-Deficient Mice
CTLs are critical for immunity to virus, and so we exam-
ined the ability of Spi6 KO mice to mount a CTL response
and clear LCMV. We examined the requirement for Spi6
in immunity to high doses (106 pfu) of the clone 13 vari-
ant of LCMV Armstrong, which has previously revealed
deficiencies in CTL immunity to virus (Ahmed et al.,
1984; Matloubian et al., 1999). Ex vivo CTL activity was
measured in standard 51Cr-release assays with gp33
pulsed targets. We observed a consistent deficit in
LCMV-specific CTL activity in Spi6 KO mice over the
course of clone 13 infection (Figure 4A). For example,
on day 10, there was a 6-fold decrease (p = 2 3 1024)
in CTL activity in Spi6 KO mice (2.3% 6 0.7% specific
lysis, n = 5 mice; Splenocyte/Target ratio [S/T] = 50:1)compared to B6 controls (13.6% 6 1.7% specific lysis,
n = 5 mice; S/T = 50:1).
The deficit in CTL activity resulted in correspondingly
defective clearance of clone 13 (Figure 4B). Plaque as-
says revealed that the titer of LCMV was about 10 times
higher in Spi6 KO mice on day 6 (p = 0.0067), day 8 (p =
0.0043), and day 10 (p = 0.002) after infection. The lower
number of LCMV-specific CTLs in Spi6 KO mice, rather
than any intrinsic defect in killing, results in impaired
CTLs activity. This was because, on day 8 after infection
with LCMV, although we observed defective CTL activity
in Spi6 KO mice as expected (Figure 4C), when specific
lysis was normalized for the number of input LCMV-
specific CTLs (gp33+ CD8+ cells), there was no signifi-
cant (p = 0.63; CTL/Target ratio = 1.0) difference be-
tween Spi6 KO mice and B6 controls (Figure 4D).
We determined whether the impaired CTL-mediated
clearance of clone 13 LCMV in Spi6 KO mice was due
to a cell-autonomous defective in CD8 T cells. Naive
P14 CD8 T cells from Spi6 KO and B6 mice were adop-
tively transferred into B6 recipients, which were then in-
fected with clone 13 LCMV. On day 6, gp33-specific CTL
activity was 5 times higher (S/T = 50:1; p = 63 1024) in B6
recipients of B6 P14 CD8 T cells (Figure 4E) than the en-
dogenous level in similarly infected B6 mice on day 6
(Figure 4A). Therefore, the majority of LCMV-specific
CTLs in B6 recipients are derived from donor P14 CD8
T cells on day 6 after infection with clone 13 LCMV. There
was significantly lower LCMV-specific CTL activity de-
rived from Spi6 KO P14 CD8 T cell donor cells (Fig-
ure 4E). For example, there was a 5-fold decrease (p =
1 3 1024) in donor Spi6 KO CTLs (3.6%6 1.2% specific
lysis, n = 5 mice; S/T = 5.6) compared to donor B6 con-
trols (19.1%6 1.9% specific lysis, n = 5 mice; S/T = 5.6).
The defect in donor Spi6 KO CTLs specific for clone
13 resulted in defective clearance, as evidenced by a
Spi6 Protects CTLs from Granzyme B
455Figure 4. Impaired CTL Immunity in Spi6 KO
Mice
B6 and Spi6 KO mice were infected with
LCMV clone 13 (106 pfu/mouse i.v.).
(A) Ex vivo anti-LCMV CTL activity was
measured by determining % specific lysis of
51Cr-labeled RMA target (T) cells (H-2b)
pulsed with LCMV gp33 peptide (mean of
four determinations) by splenocytes (S) from
infected mice. Data are the mean % specific
Cr51-release6 SEM (n = 5 mice) at a S/T ratio
of 50:1.
(B) Titer of clone 13 LCMV determined in
spleen homogenates by plaque assay on
Vero cells. Data are the mean titer expressed
as pfu per mg spleen 6 SEM (n = 5 mice).
(C) Ex vivo anti-LCMV CTL activity deter-
mined as % specific lysis gp33-pulsed
targets on day 8 after infection with LCMV
Armstrong (2 3 105 pfu/mouse i.p.). Data are
the mean of four determinations of % specific
Cr51-release from individual mice over a range
of S/T ratios.
(D) Ex vivo anti-LCMV CTL activity was mea-
sured as in (A) at various ratios of gp33+ CD8+
(CTL) to targets (T). P14 CD8 T cells (104) were
purified from B6 or Spi6 KO mice and adop-
tively transferred to wild-type B6 mice, then
infected with LCMV clone 13 (106 pfu/mouse
i.v.).
(E) Ex vivo anti-LCMV CTL activity deter-
mined as % specific lysis gp33-pulsed tar-
gets on day 6 after infection. Data are the
mean % specific Cr51-release 6 SEM (n = 5
mice) over a range of S/T ratios.
(F) Titer of clone 13 LCMV from the spleens of
recipient mice on day 6 after infection. Data
are the mean titer expressed as pfu per mg
spleen 6 SEM (n = 5 mice).4-fold increase in titer (p = 0.004) (Figure 4F). We
conclude that deficiency in Spi6 directly results in the
defective survival of CD8 T cells leading to impaired
CTL activity and clearance of LCMV.
Spi6 Suppresses Cytoplasmic GrB in CTLs
It has been suggested that leakage of GrB from granules
into the cytoplasm can lead to the activation-induced
cell death of cytotoxic lymphocytes (Ida et al., 2003).
Therefore, we examined whether Spi6 was required to
protect against this pathway of death in CTLs. LCMV-
specific CTLs were generated by culturing spleen cells
from P14 mice with gp33 for 2 days in vitro (>90% of
viable cells) (Phillips et al., 2004), then subjected to sub-
cellular fractionation (Sun et al., 1996). Western blots af-
ter reducing SDS-PAGE revealed Spi6 in the cytoplasm
but not granule fractions of B6 CTLs (Figure 5A). The
subcellular localization of Spi6 to the cytoplasm is con-
sistent with the lack of a secretory signal, as has been
observed for its human homolog PI9 in CTLs (Sun
et al., 1996). As expected, Spi6 was absent from Spi6
KO CTLs. A 67 kDa form of Spi6 was present in the cyto-
sol of B6 CTLs but not GrB KO CTLs. Probing Spi6 KO
CTLs with anti-GrB antiserum failed to detect the 67
kDa form, confirming it as a SDS-stable complex be-
tween Spi6 and GrB (Figure 5A).
Measurement of GrA activity by a specific substrate
(Odake et al., 1991) served as a marker for granule integ-rity independent of GrB. As expected, the specific activ-
ity of GrA was about 4 times higher (p = 33 1024) in gran-
ule compared to the cytosol fraction of GrB KO CTLs
(Figure 5B). Enzyme assays revealed significantly (p =
0.004) increased specific activity of GrB in the cytoplasm
of Spi6 KO compared to B6 CTLs (Figure 5B). Consistent
with its specificity as a serpin of GrB (Sun et al., 1997),
we conclude that Spi6 inhibits cytoplasmic GrB through
the formation of covalent complexes. We observed
lower specific activity of the caspase 3 executioner pro-
tease (Budihardjo et al., 1999) in the cytoplasm of GrB
KO CTLs (p = 2 3 1024), indicating that endogenous
GrB induces apoptosis of CTLs (Figure 5B). There was
a corresponding increase in the specific activity of cas-
pase 3 in the cytoplasm of Spi6 KO CTLs (p = 0.002)
(Figure 5B). Since substrates cleaved by GrB that trigger
apoptosis are located in the cytoplasm (Russell and Ley,
2002), we conclude that the increased apoptosis in Spi6
KO CTLs is at least in part due to increased GrB activity
in the cytoplasm.
Inhibition of GrB by Spi6 Ensures the Integrity
of Cytotoxic Granules
In addition to suppressing the activity of cytoplasmic
GrB, Spi6 also ensured the integrity of cytotoxic gran-
ules. Subcellular fractionation studies revealed a de-
crease in the specific activity of both GrB and GrA in
the granules and an increase in the cytoplasm of Spi6
Immunity
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plasmic GrB and Apoptosis in CTLs
(A) Western blots of reducing SDS-PAGE
from the cytosol and granules of wild-type
B6, Spi6 KO, or GrB KO P14 CTLs.
(B) Mean specific activity (SA) 6 SEM of GrA,
GrB, and caspase 3 (casp 3) from CTLs (n = 4
mice).KO CTLs (Figure 5B). However, it is possible that the
rupture of granules during the subcellular fractionation
procedure may result in granzyme activity in cytosolic
fractions. Therefore, we used confocal immunofluores-
cence microscopy (CIM) to examine the effect of Spi6
deficiency on granule stability in intact CTLs. The
frequency of Spi6 KO CTLs devoid of GrB+ granules
(>0.1 mm in diameter) was about 3 times greater than
for B6 CTLs (p = 0.03), resulting in a 2-fold decrease
(p = 0.03) in the mean number of GrB+ granules per
Spi6 KO CTL (Figures 6A and 6B). Furthermore, there
was a corresponding increase in GrB staining in the
cytoplasm of Spi6 KO CTLs. (Figure 6A). We also ob-
served a loss of GrB+ Pfn+ granules in Spi6 KO CTLs
(Figure 6C), implying that Spi6 prevents GrB leakage
into the cytoplasm by ensuring general granule integrity.
Granule vesicles from murine CTLs are composed of
several clustered membrane bound electron-dense
cores with a diameter of about 100 nm (Peters et al.,
1991). We used transmission electron microscopy
(TEM) to determine the number of electron-dense cores
in 0.1 mm thick sections (n = 300) of Spi6 P14 CTLs, and
after extrapolation based on the cell volume, the total
number per CTL (Peters et al., 1991). Spi6 KO CTLs con-
tained 7 times (p = 0.02) fewer electron-dense cores
(14 6 4) than B6 CTLs (102 6 20), although there was
no significant difference (p = 0.5) in the mean diameter
of the electron-dense cores (B6 120 6 30 nm, Spi6 KO
125 6 26 nm). Representative examples of electron mi-
crographs of B6 and Spi6 CTLs are shown in Figure 6D.
The defect in the number of granule cores in Spi6 CTLs is
consistent with the decrease in the number of GrnB+
Pfn+ granules revealed by CIM (Figure 6C). As expected,
about 40% of the electron-dense granule cores in wild-
type CTLs were found in clusters of three or more, indi-
cating the presence of a granule vesicle (Peters et al.,
1991). However, we did not observe any clustering of
the electron-dense granule cores into granule structures
in Spi6 KO CTLs (Figure 6D). Thus, as well as reducing
the number of core vesicles, Spi6 deficiency also seems
to disrupt the organization of these cores into granule
vesicles.The defect in granule integrity was GrB dependent be-
cause inhibition of GrB by Z-AAD-CMK (Gong et al.,
1999) gave a significant (p = 2 3 1026) increase in the
number of granules in Spi6 KO CTLs (Figure 6E). As we
observed before (Figure 5B), there was a 2-fold decrease
(p = 93 1025) in granule-associated GrA-specific activity
in Spi6 KO CTLs compared to B6 control CTLs (Fig-
ure 6F). The defect in Spi6 KO CTLs could be corrected
in Spi6 KO x GrB KO CTLs, as indicated by a complete
rescue of GrA-specific activity in granules (Figure 6E).
We conclude that the increased GrB activity in the cyto-
plasm of Spi6 KO is the catalyst for granule breakdown
and amplification of GrB-mediated effects. The signifi-
cant (p = 0.004) increase in granule-specific GrA activity
in GrB KO CTLs over the level in B6 CTLs (Figure 6F) sug-
gests that GrB-catalyzed breakdown of granules may
occur in wild-type CTLs. This is supported by the in-
crease (p = 0.01) in the mean number of electron-dense
granule cores in GrB CTLs (150 6 67, n = 300 cell sec-
tions) compared to B6 CTLs (1026 20) (Figure S1).
Discussion
Studies that describe the expression of PI9 and Spi6 in
leukocytes and inflammatory sites have led to the sug-
gestion that serpins protect against GrB during immune
reactions (Bladergroen et al., 2001; Hirst et al., 2003).
These observations have been complemented by ec-
topic overexpression studies that show the potential
for Spi6 in protecting from GrB-mediated death (Me-
dema et al., 2001b; Phillips et al., 2004). However, artifi-
cially high levels of Spi6 expression were required for
cyto-protection (Medema et al., 2001b; Phillips et al.,
2004), and so the physiological requirement for Spi6
was not tested. To address this issue, we generated
Spi6 KO mice and examined the viability, function, and
structure of CTLs.
We show that Spi6 protects CTLs from their own GrB
by suppressing activity in the cytoplasm. The break-
down of cytotoxic granules by GrB in the cytoplasm
was unexpected, but likely amplifies the release of GrB
and induction of apoptosis (Figure 7). How the increased
Spi6 Protects CTLs from Granzyme B
457Figure 6. Spi6 Deficiency Destabilizes Cytotoxic Granules
(A) Visualization of GrB+ granules in P14 CTLs by CIM. Nuclei were stained by DAPI. Scale bar equals 5 mm.
(B) Distribution of the number of GrB+ granules (diameter > 0.1 mm) per P14 CTL (n = 300 cells) measured by CIM. Mean values are indicated.
(C) Visualization of GrB+ Pfn+ granules in P14 CTLs by CIM. Scale bar equals 5 mm.
(D) TEM (34060 magnification) of P14 CTLs from B6 and Spi6 KO mice. The arrow indicates electron dense granule cores (a cluster of seven in B6
CTLs, one in Spi6 KO CTL). Scale bar equals 2 mm.
(E) Effect of Z-AAD (OMe)-CMK on the number of GrB+ granules (diameter > 0.1 mm) per P14 CTL 6 SEM (n = 300 cells) measured by CIM.
(F) Mean SA of GrA in the granule fractions of P14 CTLs 6 SEM (n = 4 mice).cytoplasmic GrB in Spi6 KO CTLs leads to granule
breakdown is unclear but could involve direct targets
on the granule or could be a more indirect consequence
of biochemical events triggered by cytoplasmic GrB
(Russell and Ley, 2002). The potency of GrB as a CTL
effector molecule likely explains why less than a 2-fold
increase in cytoplasmic GrB activity (Figure 5B) results
in the near complete loss (10%–20% of wild-type level)
of Spi6 KO CTLs in vivo (Figure 2). GrB kills by triggeringmultiple apoptotic pathways involving caspases and mi-
tochondrial dysfunction in addition to DNA fragmenta-
tion (Russell and Ley, 2002). By directly targeting GrB,
Spi6 can potentially suppress all of the toxic effects of
a CTL effector molecule. It has been suggested that in-
hibition of another CTL effector molecule—Pfn—by ca-
thepsin B also protects CTLs from self-inflicted damage
(Balaji et al., 2002). However, in vivo studies indicate that
cathepsin B induces the apoptosis of CTLs (Liu et al.,Figure 7. Spi6 Inhibits GrB-Mediated Apo-
ptosis of CTLs
Spi6 inhibits GrB in the cytoplasm of wild-type
(wt) CTLs (nucleus in dark gray) through the
formation of an irreversible complex. The inhi-
bition of GrB (crossed line) blocks the cleav-
age and activation of target enzymes and
the induction of death (crossed line). The
breakdown of granule integrity and the re-
lease of more GrB, either directly by cytoplas-
mic GrB or by downstream targets, is thus
inhibited by Spi6. Cytoplasmic GrB is not
blocked in Spi6 KO CTLs and so there is in-
creased death. A positive feedback loop
whereby GrB release into the cytoplasm cata-
lyzes further leakage from granules then en-
sues because GrB causes granule damage.
There is no GrB-mediated breakdown of gran-
ules in GrB KO CTLs resulting in increased
granule number and decreased death.
Immunity
4582004). Thus, Spi6 seems to be unique as an inhibitor of
self-inflicted damage by CTLs that has been validated
in vivo.
The expression of peptide antigen/MHC (pMHC) on
CTLs after infection by virus (Hanon et al., 2000) or after
reexpression of target cell pMHC after killing (Huang
et al., 1999) can lead to fratricide. However, our findings
with Spi6 are consistent with the induction of suicide by
endogenous GrB in the cytoplasm of CTLs (Opferman
et al., 2001) and NK cells (Ida et al., 2003). In our studies,
we find that Spi6 KO CTLs undergo increased apoptosis
because their own granules release GrB into the cyto-
plasm. In addition, GrB-mediated granule breakdown
likely also occurs in wild-type CTLs (Figure 6E). Although
our studies do not rule out the possibility that fratricide
of CTLs is a physiological mechanism for clearing
CTLs in vivo, they do show that GrB-mediated death
may occur in wild-type CTLs without fratricide.
Cytotoxic T cells from patients with Chediak-Higashi
(Baetz et al., 1995; Barbosa et al., 1996; Stinchcombe
et al., 2000; Ward et al., 2000) and Griscelli (Menasche
et al., 2000) syndromes and from the relevant mouse
models (Beige [Perou et al., 1996a, 1996b] and Ashen
[Wilson et al., 2000]) have defective granule killing. This
is due to mutations that disrupt the secretion of gran-
zymes but do not diminish the number of cytotoxic gran-
ules. Therefore, the decrease in the number of cytotoxic
granules we observed in Spi6 KO CTLs was unexpected.
Those ex vivo Spi6 KO CTLs we could recover were not
impaired in their ability to kill (Figure 4D). This implies
that ‘‘granule-less’’ Spi6 KO CTLs are likely to be very
short lived in vivo, presumably because of their in-
creased susceptibility to apoptosis. CIM revealed that
Spi6 KO harbor fewer GrB+ Pfn+ granules (Figures 6A–
6C), which was confirmed when TEM revealed a corre-
sponding deficit in the number of electron-dense gran-
ule cores (Figure 6D). In wild-type mice, granule vesicles
are composed of clustered membrane bound, electron-
dense cores (Peters et al., 1991). We did not observe any
clustering of electron-dense cores in Spi6 KO CTLs,
suggesting a disruption in both the stability and organi-
zation of core vesicles within granule vesicles. That GrB
is the cause of granule instability CTLs is demonstrated
by our observations that GrB synthetic inhibitors (Fig-
ure 6E) and genetic deficiency (Figure 6F) can restore
the integrity of granules in Spi6 KO CTLs.
Given the role of Spi6 in protecting CTLs from self-
inflicted damage, one might predict that some human
CTLs immunodeficiencies may potentially also be due
to mutations in the PI9 human homolog. Ectopic expres-
sion of PI9 can enhance human CTL killing (Hirst et al.,
2003), and so suppression of cytoplasmic GrB may
have therapeutic value in rescuing defective CTL func-
tion in chronic viral infections (McMichael, 1998). PI9 is
also upregulated in cells in immune-privileged sites (Bla-
dergroen et al., 2001) and so may also protect against
inflammatory disease by suppressing GrB.
Experimental Procedures
Mice
Spi6 cDNA (Phillips et al., 2004) was used to clone mouse genomic
DNA containing the Spi6 locus (Serpin b9) from a bacterial artificial
chromosome (BAC) library (129/Sv strain RPCI-22, Res Gen). The50 homology region (4.1 kb Sac II-Kpn I fragment) and the 30 homol-
ogy region (3.6 kb Not I-Xho I fragment) were cloned on either side
of the neo gene (1.8 kb Kpn I-Not I fragment) flanked by loxP recom-
bination sites (Kuhn et al., 1995). C57BL/6 ES cells (Ware et al., 2003)
were transfected with targeting vector (50 mg). DNA from G418-
resistant clones was digested with Spe I and Hind III and hybridized
with probes to detect wild-type (50, 7.6 kb; 30, 9.8 kb) and mutant
(50, 6.9 kb; 30, 5.8 kb) alleles. ES cells from targeted clones (2/398)
were transfected (30 mg) with Cre (pBS185, Invitrogen), and excision
of the neo after loxP site-specific recombination was detected by the
presence of a 5.8 kb band after blotting with 50-probe (Kuhn et al.,
1995). C57BL/6 ES cells were microinjected into BALB/c blastocysts
to produce chimeric mice, which were then backcrossed against
wild-type C57BL/6 mice (Jackson Laboratory). C57BL/6 Spi6+/2
mice (from two independently targeted ES cell clones) were inter-
crossed to generate C57BL/6 Spi62/2 mice (Spi6 KO mice), which
were born at a Mendelian frequency.
Spi6 KO mice were crossed with GrB2/2 C57BL/6 (GrB KO) (Heu-
sel et al., 1994) (Jackson Laboratory) to generate C57BL/6 Spi62/2
GrB2/2 mice (Spi6 KO x GrB KO). C57BL/6 P14 TCR+/2 transgenic
mice (B6 P14 mice) (Pircher et al., 1990) were crossed with either
Spi6 KO or Spi6 KO x GrB KO mice to produce C57BL/6 Spi6 KO
P14 TCR+/2 (Spi6 KO P14 mice) or C57BL/6 Spi6 KO x GrB KO
P14 TCR+/2 (Spi6 KO x GrB KO P14 mice) transgenic mice.
C57BL/6 CD45.1 congenic mice were purchased from Taconic. All
mice were maintained and bred under standard specific pathogen-
free (SPF) conditions. All experiments with mice were performed in
compliance with the University of Chicago Institutional Animal
Care and Use Committee regulations.
Real-Time PCR
Leukocytes were purified (>95%) for real-time PCR analysis from
splenocytes by magnetic beads conjugated to phenotypic markers
(Miltenyi Biotec). Macrophages were generated from bone marrow
cultured in media containing macrophage colony stimulating factor
by standard protocols (Coligan et al., 1995). DCs (immature) were
generated from bone marrow, as described before (Lutz et al.,
1999). Neutrophils were recovered from the peritoneum by lavage
4 hr after i.p. injection with 15% glycogen (1 ml), as described before
(Lopez-Boado et al., 2004). RNA was extracted from purified cell
populations by TriZOL Reagent (Invitrogen), and then cDNA was
generated by Superscript First-Strand Synthesis System for
RT-PCR (Invitrogen) (Medhurst et al., 2000). Primer and probe
sequences for Spi6, Spi3, and cyclophilin A are described in Supple-
mental Experimental Procedures online and were designed by
Primer Express software (PE Applied Biosystems). The data were
calculated as the ratio of candidate RNA expression/amount of
cyclophilin A, as before (Liu et al., 2004).
Infections
Mice were infected by either i.p. injection (23 105 pfu) of LCMV Arm-
strong (Phillips et al., 2004) or i.v. injection (106 pfu) of the clone 13
variant of LCMV Armstrong (Ahmed et al., 1984). For LM, mice
were infected by i.v. injection of DPL-1942 (105 cfu), which has
been engineered to express ovalbumin and in C57BL/6 mice gener-
ates the H-2Kb-restricted peptide epitope (SIINFEKL: OVA) (Pope
et al., 2001). LCMV was titered on monolayers of Vero cells (Ahmed
et al., 1984).
Flow Cytometry
The following mAbs were used (BD-Pharmingen): anti-CD8a (allo-
phycocyanin [APC]-labeled), anti-CD45.2-fluorescein isothiocynate
[FITC] or R-phycoerythrin [PE], anti-CD11b+-FITC, anti-F4/80-PE,
anti-DX5-PE, anti-B220-FITC, anti-BrdU-FITC (IgG1) and IgG1
isotype control-FITC. H-2Db-tetramers with gp 33 [KAVYNFATM]
(Phillips et al., 2004) or H-2Kb-tetramers with OVA were labeled
with streptavidin-PE (Beckman Coulter). Thymocytes, PBLs and
splenocytes were prepared and stained with tetramers and mAbs
as before (Phillips et al., 2004). Apoptosis of live cells (propidium
iodide-negative) was measured with YOPRO-1 dye (green fluores-
cence) (Molecular Probes), as before (Opferman et al., 2001). Intra-
cellular staining with anti-BrdU mAb was used to determine BrdU in-
corporation in CD45.2+ gp33+ CD8+ cells, as before (Phillips et al.,
2004).
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Naive CD8+ cells were purified (>90%) from the spleens of P14 mice
(CD45.2+) by positively sorting with anti-CD8 magnetic beads (Milte-
nyi Biotec) and adoptively transferred (104) by i.v. injection into
C57BL/6 CD45.1 mice and after 1 day infected with LCMV. To mea-
sure P14 CD8 T cell division, recipients were given BrdU in their
drinking water (0.8 mg/ml) for 8 days after LCMV infection (Phillips
et al., 2004).
Ex Vivo CTL Assays
To measure ex vivo CTL activity after LCMV infection, RMA targets
were pulsed with gp33 (1027 M) for 1 hr and labeled with 51Cr2,
then incubated with viable splenic leukocytes over a range of ratios
in quadruplicate. The percentage specific lysis was determined after
4 hr as follows: % specific release = (specific release2 spontaneous
release)/(maximum release 3 spontaneous release) 3 100 (Opfer-
man et al., 2001). The percentage specific lysis of RMA cells in the
absence of gp33 was <10% and the spontaneous release was
<10% of the maximum release.
Subcellular Fractionation of CTLs
Spleen cells (106/ml) from B6 P14 mice, Spi6 KO P14 mice, or Spi6
KO x GrB KO P14 mice were cultured with LCMV gp33 peptide
[KAVYNFATM] (1026 M) and IL-2 (10 U/ml) for 2 days to generate
CTLs (Phillips et al., 2004). CTLs were lysed by sonication in hypo-
tonic buffer (50 mM PIPES, 50 mM KCL, 5 mM EGTA, 2 mM MgCl2,
5 mM DTT [pH 7.6]), then centrifuged at 3000 3 g for 20 min to re-
move nuclei, then 15,0003 g for 30 min to give cytosol (supernatant)
and granule (pellet) fractions (Sun et al., 1996). The granule pellet
was resuspended in 1% Triton X-100, 10 mM Tris.HCl, 150 mM
NaCl (pH 7.6) for 30 min on ice.
Western Blotting
Antiserum specific to a Spi6 peptide (amino acids 35–47)
([C]RKLNKPDRKYSLR) was raised in rabbits by standard proce-
dures (Coligan et al., 1995). In brief, two rabbits were immunized
with the peptide conjugated to KLH and then boosted twice with im-
munogen over a period of 3 months. Anti-Spi6 antibodies were affin-
ity purified on columns of immunizing peptide, eluted in 3M KSCN,
and then dialyzed against PBS. Protein (50 mg) was resolved by re-
ducing SDS-PAGE, then immunoblotted and probed with anti-Spi6
antiserum (7 mg/ml) and goat anti-rabbit IgG conjugated to horserad-
ish peroxidase (HRP) (2 mg/ml) (Sigma-Aldrich), then visualized by
chemiluminescence (ECL-kit, Amersham). Blots were also probed
with goat anti-mouse GrB (0.2 mg/ml) (R&D Systems) and anti-goat
IgG HRP (2 mg/ml) (Sigma-Aldrich) or with anti-actin monoclonal an-
tibody clone ACTN05 (0.5 mg/ml) (Sigma Aldrich) and anti-mouse
IgG-HRP (2 mg/ml) (Sigma-Aldrich).
Protease Assays
Colorimetric assays for GrB were performed in reaction buffer with
Ac-IEPD-pNA at 0.2 mM (Liu et al., 2003) and GrA with BLT (Na-ben-
zyloxycarbonyl-L-lysine thiobenzyl ester) at 0.2 mM (Odake et al.,
1991) and Ellman’s reagent at 1.76 mM in reaction buffer (100 mM
Tris-HCl) at 30ºC. Assays for caspase 3 were performed in reaction
buffer (10 mM PIPES [pH 7.4], 8 mM DTT, 2 mM EDTA, 0.1% CHAPS)
at 30ºC with Ac-DEVD-pNA (Calbiochem) at 0.2 mM (Liu et al., 2003).
Specific activity was determined by normalizing for the amount of
protein. Units of activity were as defined before (Liu et al., 2003).
To inhibit GrB (Gong et al., 1999; Odake et al., 1991), Z-AAD
(OMe)-CMK (12.5 mM; Sigma Aldrich) was added for the duration
of 2 day cultures. Under these conditions, we observed 100% inhibi-
tion of GrB in both the granule and cytoplasmic fractions.
CIM
P14 CTLs were seeded on wells of poly-L-Lysine-coated slides, then
fixed and permeabilized in acetone/methanol and blocked with 10%
normal horse serum in PBS for 60 min at 20ºC. P14 CTLs were
stained with anti-murine GrB Ab (1:200; R&D Systems) and anti-mu-
rine Pfn P1-8 mAb (1:100; Kamiya Biomedical Co) for 60 min at 20ºC
in 2% BSA/PBS, then biotin-conjugated mouse anti-Rat mAb (1:100;
BD Pharmingen) and FITC conjugated rabbit anti-goat antibody
(1:200; Molecular Probes) for 60 min at 20ºC. After washing with
PBS, cells were further incubated with streptavidin-PE (1 mg/ml;BD Pharmingen) and DAPI (Sigma Aldrich), washed, and mounted
in Vectashield (Vector Labs). Cells were examined with a Leica
SP2 AOBS spectral laser scanning confocal microscope operated
with the software LCS 2.5v1347. The mean number of granules
was determined from the counting of multiple cell layers (100 cells
in 3 separate counts, n = 300) with a granule defined as point of stain-
ing with a diameter >0.1 mm.
TEM
Cells were stained with uranyl acetate/lead citrate, as described in
Supplemental Experimental Procedures. An electron microscope
(FEI Tecnai F30) at 300 kV was used for examination. Electron-dense
core vesicles were counted in 64 mm2 cell areas (n = 300), and then
the total mean number per cell was determined assuming a mean
cell volume of 523 mm3 (mean number per 64 mm23 8.2 = mean total
number per cell).
Statistics
The significance of difference was measured using two-tailed Stu-
dent’s t tests.
Supplemental Data
Supplemental Data include one figure, three tables, and Supplemen-
tal Experimental Procedures and can be found with this article online
at http://www.immunity.com/cgi/content/full/24/4/451/DC1/.
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